Carina Biotech Limited
Monday, February 26, 2024
Carina Biotech is a clinical stage immuno-oncology company developing CAR-T and other adoptive cell therapies for the treatment of solid cancers. In addition to its LGR5-targeted CAR-T cell therapy CNA3103 for advanced colorectal cancer, Carina has a deep pipeline of CAR-T programs as well as platform technologies for the positioning of CAR-T cells within solid tumours, to enhance potency and induce “serial” killing that is capable of memory and a proprietary 5-day manufacturing process.
CEO/Top Company Official
Deborah Rathjen PhD CEO & Managing Director
Lead Product in Development
Carina’s proprietary CNA3103 CAR-T cell targets LGR5, a cancer stem cell marker that is highly expressed on advanced colorectal cancer and some other cancers. CNA3103 is in Phase 1 in patients with metastatic colon cancer. In colorectal cancer patients, LGR5 expression has been correlated with poor prognosis. Cancer stem cells are a small sub-population of cells within a tumour with the ability to self-renew, differentiate into the many cell types of a tumour, initiate new tumours, and resist chemotherapy and radiotherapy (leading to relapses). By targeting cancer stem cells, it is anticipated that this therapy will reduce the tumour’s ability to generate new cancer cells, resulting in durable tumour suppression and preventing the relapses that are very common in patients with colorectal cancer. Carina’s pre-clinical studies of CNA3103 have shown promising results with complete tumour regression and no tumour recurrence following a single administration. CNA3103 has also been demonstrated to reject tumour re-challenge.
Development Phase of Primary Product